Standard Chem & Pharm CO., LTD. (1720.TW)
TWD 58.7
(-0.51%)
TWD 58.7
(-0.51%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 834.88 Million TWD | -27.63% |
| 2022 | 1.15 Billion TWD | 63.23% |
| 2021 | 706.73 Million TWD | 34.83% |
| 2020 | 524.17 Million TWD | 39.23% |
| 2019 | 376.48 Million TWD | 0.57% |
| 2018 | 374.35 Million TWD | 3.05% |
| 2017 | 363.28 Million TWD | 6.78% |
| 2016 | 340.21 Million TWD | -2.21% |
| 2015 | 347.89 Million TWD | -7.04% |
| 2014 | 374.23 Million TWD | 25.42% |
| 2013 | 298.38 Million TWD | 9.93% |
| 2012 | 271.42 Million TWD | 10.0% |
| 2011 | 246.74 Million TWD | 17.47% |
| 2010 | 210.05 Million TWD | -28.42% |
| 2009 | 293.46 Million TWD | 6.87% |
| 2008 | 274.59 Million TWD | 2.57% |
| 2007 | 267.71 Million TWD | -17.23% |
| 2006 | 323.44 Million TWD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 252.7 Million TWD | 56.27% |
| 2024 Q2 | 215.76 Million TWD | -14.62% |
| 2023 Q4 | 161.71 Million TWD | -27.77% |
| 2023 Q2 | 238.31 Million TWD | -19.58% |
| 2023 Q1 | 296.32 Million TWD | 69.42% |
| 2023 Q3 | 223.88 Million TWD | -6.06% |
| 2023 FY | 834.88 Million TWD | -27.63% |
| 2022 Q4 | 174.9 Million TWD | -51.96% |
| 2022 FY | 1.15 Billion TWD | 63.23% |
| 2022 Q3 | 364.08 Million TWD | 10.4% |
| 2022 Q2 | 329.79 Million TWD | 41.37% |
| 2022 Q1 | 233.27 Million TWD | 34.88% |
| 2021 Q3 | 159.27 Million TWD | -4.16% |
| 2021 Q4 | 172.95 Million TWD | 8.59% |
| 2021 Q1 | 208.33 Million TWD | 30.12% |
| 2021 FY | 706.73 Million TWD | 34.83% |
| 2021 Q2 | 166.17 Million TWD | -20.24% |
| 2020 Q1 | 120.09 Million TWD | 23.34% |
| 2020 Q4 | 160.11 Million TWD | 40.21% |
| 2020 Q3 | 114.19 Million TWD | -12.0% |
| 2020 FY | 524.17 Million TWD | 39.23% |
| 2020 Q2 | 129.77 Million TWD | 8.06% |
| 2019 Q2 | 99.09 Million TWD | 38.02% |
| 2019 FY | 376.48 Million TWD | 0.57% |
| 2019 Q4 | 97.36 Million TWD | -10.03% |
| 2019 Q3 | 108.22 Million TWD | 9.21% |
| 2019 Q1 | 71.79 Million TWD | -24.04% |
| 2018 FY | 374.35 Million TWD | 3.05% |
| 2018 Q4 | 94.51 Million TWD | -19.76% |
| 2018 Q3 | 117.79 Million TWD | 18.85% |
| 2018 Q2 | 99.1 Million TWD | 57.45% |
| 2018 Q1 | 62.94 Million TWD | 27.7% |
| 2017 FY | 363.28 Million TWD | 6.78% |
| 2017 Q1 | 59.07 Million TWD | -25.06% |
| 2017 Q4 | 49.29 Million TWD | -68.22% |
| 2017 Q3 | 155.1 Million TWD | 55.39% |
| 2017 Q2 | 99.81 Million TWD | 68.98% |
| 2016 Q2 | 71.57 Million TWD | -10.89% |
| 2016 FY | 340.21 Million TWD | -2.21% |
| 2016 Q1 | 80.32 Million TWD | 4.98% |
| 2016 Q4 | 78.82 Million TWD | -28.01% |
| 2016 Q3 | 109.49 Million TWD | 52.97% |
| 2015 FY | 347.89 Million TWD | -7.04% |
| 2015 Q4 | 76.51 Million TWD | -18.8% |
| 2015 Q3 | 94.22 Million TWD | 26.91% |
| 2015 Q2 | 74.24 Million TWD | -27.85% |
| 2015 Q1 | 102.9 Million TWD | 39.44% |
| 2014 Q4 | 73.8 Million TWD | -24.6% |
| 2014 FY | 374.23 Million TWD | 25.42% |
| 2014 Q1 | 96.07 Million TWD | 182.68% |
| 2014 Q2 | 106.48 Million TWD | 10.83% |
| 2014 Q3 | 97.87 Million TWD | -8.08% |
| 2013 Q4 | 33.98 Million TWD | -39.2% |
| 2013 FY | 298.38 Million TWD | 9.93% |
| 2013 Q3 | 55.89 Million TWD | -38.61% |
| 2013 Q1 | 117.46 Million TWD | 80.42% |
| 2013 Q2 | 91.04 Million TWD | -22.49% |
| 2012 Q3 | 74.59 Million TWD | 61.8% |
| 2012 Q4 | 65.1 Million TWD | -12.72% |
| 2012 Q2 | 46.1 Million TWD | -47.25% |
| 2012 FY | 271.42 Million TWD | 10.0% |
| 2012 Q1 | 87.4 Million TWD | 19.49% |
| 2011 Q3 | 53.95 Million TWD | -16.72% |
| 2011 Q4 | 73.15 Million TWD | 35.58% |
| 2011 FY | 246.74 Million TWD | 17.47% |
| 2011 Q1 | 54.85 Million TWD | 223.27% |
| 2011 Q2 | 64.78 Million TWD | 18.1% |
| 2010 Q1 | 57.75 Million TWD | 0.0% |
| 2010 FY | 210.05 Million TWD | -28.42% |
| 2010 Q4 | 16.96 Million TWD | -72.86% |
| 2010 Q3 | 62.51 Million TWD | -14.13% |
| 2010 Q2 | 72.8 Million TWD | 26.06% |
| 2009 FY | 293.46 Million TWD | 6.87% |
| 2008 FY | 274.59 Million TWD | 2.57% |
| 2007 FY | 267.71 Million TWD | -17.23% |
| 2006 FY | 323.44 Million TWD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Grape King Bio Ltd | 1.45 Billion TWD | 42.53% |
| Maywufa Company Ltd. | 169.09 Million TWD | -393.729% |
| ScinoPharm Taiwan, Ltd. | 287.05 Million TWD | -190.844% |
| Lotus Pharmaceutical Co., Ltd. | 4.1 Billion TWD | 79.665% |
| LIWANLI Innovation Co., Ltd. | 5.1 Million TWD | -16260.69% |
| YungShin Global Holding Corporation | 827.3 Million TWD | -0.916% |
| PhytoHealth Corporation | -47.11 Million TWD | 1871.942% |
| SCI Pharmtech, Inc. | 294.72 Million TWD | -183.28% |
| Formosa Laboratories, Inc. | 126.24 Million TWD | -561.333% |
| PharmaEssentia Corporation | -623.83 Million TWD | 233.831% |
| Bora Pharmaceuticals Co., LTD. | 3.03 Billion TWD | 72.447% |